Quiz|Articles|October 5, 2025
Dermatology Times Spot Test: October 5, 2025
Author(s)Marie Bosslett, Assistant Editor
Listen
0:00 / 0:00
Key Takeaways
- Chronic hand eczema (CHE) significantly affects patients' quality of life, necessitating effective management strategies.
- Recent advancements in CHE pathophysiology and treatment options offer new hope for improved patient outcomes.
Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series!
Advertisement
Dermatology Times presents: Spot Test!
Each week, dive into a series of thought-provoking questions designed to test your understanding of essential topics, trends, and breakthroughs in dermatology.
This week, we'll focus on the latest news in
Do you have a set of quiz questions to share? Contact editor Marie Bosslett at
When was delgocitinib cream approved by the FDA?
What percentage of patients in the DELTA TEEN trial's delgocitinib arm achieved IGA-CHE Treatment Success at week 16?
In the same trial, which symptom showed the greatest improvement in the HESD scores for the delgocitinib group?
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
Reviewing Type 2 Inflammation Through a Different Lens
3
Derm Dispatch: What 'Free to Be Me' Means to Tori Spelling and Stella McDermott
4
How Clinicians are Navigating JAK Inhibitors and Patient Expectations in Alopecia Areata
5
